NASDAQ:CLBS

Caladrius Biosciences Competitors

$1.76
+0.05 (+2.92 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.71
Now: $1.76
$1.79
50-Day Range
$1.71
MA: $1.97
$2.29
52-Week Range
$1.25
Now: $1.76
$4.89
Volume962,365 shs
Average Volume6.12 million shs
Market Capitalization$104.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.55

Competitors

Caladrius Biosciences (NASDAQ:CLBS) Vs. FMS, DVA, SHC, PGNY, TVTY, and TLMD

Should you be buying CLBS stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Caladrius Biosciences, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and SOC Telemed (TLMD).

Caladrius Biosciences (NASDAQ:CLBS) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Caladrius Biosciences has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.

Earnings and Valuation

This table compares Caladrius Biosciences and Fresenius Medical Care AG & Co. KGaA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.94
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.12$1.34 billion$2.5314.86

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Caladrius Biosciences and Fresenius Medical Care AG & Co. KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%

Insider & Institutional Ownership

9.0% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 10.3% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Caladrius Biosciences and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
Fresenius Medical Care AG & Co. KGaA19702.35

Caladrius Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 468.18%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $45.00, indicating a potential upside of 19.68%. Given Caladrius Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Caladrius Biosciences is more favorable than Fresenius Medical Care AG & Co. KGaA.

Summary

Fresenius Medical Care AG & Co. KGaA beats Caladrius Biosciences on 8 of the 13 factors compared between the two stocks.

Caladrius Biosciences (NASDAQ:CLBS) and DaVita (NYSE:DVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Caladrius Biosciences has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Earnings and Valuation

This table compares Caladrius Biosciences and DaVita's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.94
DaVita$11.39 billion1.05$810.98 million$5.4020.19

DaVita has higher revenue and earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Caladrius Biosciences and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
DaVita7.32%43.99%5.27%

Insider & Institutional Ownership

9.0% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 91.7% of DaVita shares are held by institutional investors. 10.3% of Caladrius Biosciences shares are held by company insiders. Comparatively, 1.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Caladrius Biosciences and DaVita, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
DaVita13102.00

Caladrius Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 468.18%. DaVita has a consensus price target of $114.60, indicating a potential upside of 5.14%. Given Caladrius Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Caladrius Biosciences is more favorable than DaVita.

Summary

DaVita beats Caladrius Biosciences on 8 of the 13 factors compared between the two stocks.

Caladrius Biosciences (NASDAQ:CLBS) and Sotera Health (NYSE:SHC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Caladrius Biosciences and Sotera Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
Sotera Health001003.00

Caladrius Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 468.18%. Sotera Health has a consensus price target of $32.75, indicating a potential upside of 26.74%. Given Caladrius Biosciences' higher probable upside, equities analysts clearly believe Caladrius Biosciences is more favorable than Sotera Health.

Earnings and Valuation

This table compares Caladrius Biosciences and Sotera Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.94
Sotera HealthN/AN/AN/AN/AN/A

Profitability

This table compares Caladrius Biosciences and Sotera Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
Sotera HealthN/AN/AN/A

Insider & Institutional Ownership

9.0% of Caladrius Biosciences shares are held by institutional investors. 10.3% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sotera Health beats Caladrius Biosciences on 4 of the 7 factors compared between the two stocks.

Progyny (NASDAQ:PGNY) and Caladrius Biosciences (NASDAQ:CLBS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Volatility & Risk

Progyny has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Earnings & Valuation

This table compares Progyny and Caladrius Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Progyny$229.68 million18.04$-8,570,000.00$0.11431.82
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.94

Progyny has higher revenue and earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Progyny and Caladrius Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Progyny00603.00
Caladrius Biosciences01302.75

Progyny currently has a consensus price target of $38.8333, indicating a potential downside of 18.25%. Caladrius Biosciences has a consensus price target of $10.00, indicating a potential upside of 468.18%. Given Caladrius Biosciences' higher probable upside, analysts plainly believe Caladrius Biosciences is more favorable than Progyny.

Insider and Institutional Ownership

58.5% of Progyny shares are owned by institutional investors. Comparatively, 9.0% of Caladrius Biosciences shares are owned by institutional investors. 33.3% of Progyny shares are owned by company insiders. Comparatively, 10.3% of Caladrius Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Progyny and Caladrius Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Progyny1.03%7.43%5.04%
Caladrius BiosciencesN/A-68.33%-57.61%

Summary

Progyny beats Caladrius Biosciences on 12 of the 13 factors compared between the two stocks.

Caladrius Biosciences (NASDAQ:CLBS) and Tivity Health (NASDAQ:TVTY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Risk & Volatility

Caladrius Biosciences has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500.

Earnings & Valuation

This table compares Caladrius Biosciences and Tivity Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.94
Tivity Health$1.13 billion1.03$-286,820,000.00$2.0211.66

Caladrius Biosciences has higher earnings, but lower revenue than Tivity Health. Caladrius Biosciences is trading at a lower price-to-earnings ratio than Tivity Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for Caladrius Biosciences and Tivity Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
Tivity Health12502.50

Caladrius Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 468.18%. Tivity Health has a consensus price target of $22.1250, indicating a potential downside of 6.09%. Given Caladrius Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than Tivity Health.

Insider & Institutional Ownership

9.0% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 91.6% of Tivity Health shares are owned by institutional investors. 10.3% of Caladrius Biosciences shares are owned by insiders. Comparatively, 11.8% of Tivity Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Caladrius Biosciences and Tivity Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
Tivity Health-47.44%128.43%6.11%

Summary

Tivity Health beats Caladrius Biosciences on 9 of the 13 factors compared between the two stocks.

Caladrius Biosciences (NASDAQ:CLBS) and SOC Telemed (NASDAQ:TLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Caladrius Biosciences and SOC Telemed's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-0.94
SOC TelemedN/AN/A$20,000.00N/AN/A

Analyst Recommendations

This is a summary of recent ratings for Caladrius Biosciences and SOC Telemed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
SOC Telemed01502.83

Caladrius Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 468.18%. SOC Telemed has a consensus price target of $11.40, indicating a potential upside of 64.74%. Given Caladrius Biosciences' higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than SOC Telemed.

Insider & Institutional Ownership

9.0% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 20.7% of SOC Telemed shares are owned by institutional investors. 10.3% of Caladrius Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Caladrius Biosciences and SOC Telemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
SOC TelemedN/AN/AN/A

Summary

SOC Telemed beats Caladrius Biosciences on 6 of the 8 factors compared between the two stocks.


Caladrius Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$37.60+0.2%$22.02 billion$19.58 billion14.92
DaVita logo
DVA
DaVita
1.7$109.00+2.0%$11.92 billion$11.39 billion16.34
Sotera Health logo
SHC
Sotera Health
2.0$25.84+0.1%$7.31 billionN/A0.00Analyst Downgrade
Progyny logo
PGNY
Progyny
1.5$47.50+3.7%$4.14 billion$229.68 million431.82Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.0$23.56+0.5%$1.16 billion$1.13 billion-2.13
SOC Telemed logo
TLMD
SOC Telemed
1.6$6.92+3.0%$620.20 millionN/A0.00
Ontrak logo
OTRK
Ontrak
1.7$32.29+1.0%$571.21 million$35.10 million-18.99
Viemed Healthcare logo
VMD
Viemed Healthcare
0.9$10.28+0.9%$402.82 million$80.26 million14.28News Coverage
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.17+6.8%$82.07 millionN/A-0.34News Coverage
Gap Up
GRNV
GreenVision Acquisition
0.3$10.18+0.0%$73.17 millionN/A0.00
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.